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Previous data have demonstrated that children aged
\24 months with hemodynamically significant congenital
heart disease (HS-CHD) are at elevated risk for severe
respiratory syncytial virus (RSV) disease. However, based
upon the more recent assertion that children aged
12–23 months are not at increased risk of severe RSV, the
American Academy of Pediatrics Committee on Infectious
Diseases altered its guidance in 2014, recommending
against RSV immunoprophylaxis in children with CHD in
the second year of life [1].
Although children aged 12–23 months with CHD might
have an overall lower risk of RSV hospitalization (RSVH)
compared with children aged \12 months, given the
heterogeneity of CHD, specific CHD diagnoses can still be
associated with RSVH of greater severity. We have
recently shown that certain forms of HS-CHD are associated with high-severity RSVH in children aged
12–23 months [2]. Here we provide similar data for children aged 0–11 months.
We evaluated the impact of RSVH on mortality,
mechanical ventilation (MV), and hospital charges in
children aged 0–11 and 12–23 months with specific HSCHD diagnoses. We identified patients aged \2 years with
RSVH from the 1997–2013 National Inpatient Sample of
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US inpatient admissions, and compared patients with CHD
to age-matched cohorts without CHD.
During the 17-year study period, 35,634 RSVHs were
identified in CHD patients aged 0–11 months, with 1.2%
mortality, 19% MV, and mean charges of $23,972.
Diagnoses with the highest severity (mortality C 4%)
included cardiomyopathy, heterotaxia, total anomalous
pulmonary venous return, aortic stenosis, and CHF. Over
the same period, RSVHs for age-matched non-CHD
patients had 0.1% mortality, 3.8% MV, and mean charges
of $8488.
For CHD patients aged 12–23 months, 4813 RSVHs
were identified, with 1.5% mortality, 12% MV, and mean
charges of $19,650. The highest-severity CHD diagnoses
(mortality [ 6%) included transposition of the great vessels, cardiomyopathy, CHF, Ebstein’s anomaly, and aortic
stenosis. Age-matched non-CHD patients had 0.1% mortality, 2.3% MV, and mean charges of $8000.
We conclude that in the first 24 months of life, children with specific high-risk forms of CHD that are
hospitalized for RSV have a significantly increased risk
of morbidity/mortality and increased hospital charges
compared to children without CHD. The risk is substantially increased during the first year of life, but it
continues into the second year of life, particularly with
the above-identified CHD diagnoses (including transposition of the great vessels, cardiomyopathy, CHF,
Ebstein’s anomaly, aortic stenosis). The data from this
study reinforce the continuing need for RSV prevention
in infants and children with HS-CHD, even into the
second year of life.
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